Paulo Verardi, Ph.D.

A surge in tick activity across Connecticut is renewing concerns about Lyme disease, prompting experts to examine the environmental factors driving tick populations, the challenges of prevention, and the future role of vaccines. Recently reported by CT Community News and CTNewsJunkie, researchers are seeing unusually high numbers of ticks infected with the bacteria that causes Lyme disease, with infection rates reaching levels typically not observed until peak season. Experts point to a combination of environmental conditions, including a snowy winter that insulated overwintering ticks, milder seasonal temperatures, and continued residential expansion into wooded areas where ticks thrive. According to Dr. David Banach, an infectious disease specialist and epidemiologist at UConn Health, the increase in Lyme disease cases is influenced by multiple factors. While improved reporting may account for some of the rise, environmental conditions continue to play a significant role in the number of infections seen by clinicians each year. “Lyme disease is chronically underreported.” Dr. David Banach Dr. David Banach is an infectious diseases physician who leads UConn Health's Infection Prevention Program and serves as hospital epidemiologist. View his profile The article also explores ongoing efforts to develop new Lyme disease vaccines. Dr. Paulo Verardi, head of UConn's Department of Virology and Vaccinology, notes that vaccines could become an important tool in reducing disease risk, but cautions that vaccination alone will not solve the broader challenge posed by expanding tick populations and changing environmental conditions. Effective control, he argues, will require a combination of public education, land management, and efforts to reduce tick abundance. “To really control tickborne diseases, there needs to be more land management, public education and a drop in the overall tick population.” Dr. Paulo Verardi Dr. Paulo Verardi is a virologist who specializes in vaccine research and development. He is a Department Head and Associate Professor at UConn and a member of the Center of Excellence for Vaccine Research. View his profile As Lyme disease continues to spread across North America, understanding the intersection of climate, ecology, public health, and vaccine development is becoming increasingly important. Researchers are working to better understand why tick populations are expanding, how disease risk is changing, and what strategies can best protect people who live, work, and spend time outdoors. Covering Lyme or other tickborne diseases? We can help. To learn more about Lyme disease, tick-borne illnesses, vaccine development, infectious disease trends, and public health preparedness, connect with experts such as Dr. David Banach and Dr. Paulo Verardi, whose research and expertise help explain the growing challenges posed by tick-borne diseases.

Though the CDC has stated there are no confirmed cases of the monkeypox virus among patients under 18 in Connecticut, a handful of cases involving children have been reported across the country. Paulo Verardi, associate professor of virology and vaccinology at UConn, is taking on some of the important questions about monkeypox and children and offering his expertise and clarity regarding a topic that has many Americans and parents concerned: Are children specifically at risk? A: “Anyone is at risk of contracting monkeypox and spreading it to other people, typically by direct, close contact, such as skin to skin contact. That includes touching monkeypox lesions that sometimes can be hard to notice, or touching and using objects such as toys, clothes, and bedding of someone that is infected. “In this context, it is important to point out that the virus can stay in the environment without losing infectivity for quite some time. Children are very active, social, and tactile, so spread in settings like schools and day care facilities is something we need to consider, particularly if the outbreak continues to evolve and infections become more widespread in diverse populations.” Does the disease traditionally present differently in younger people? Is the symptomology different? A: “In general, symptoms are similar in adults and children, although for this outbreak with this specific strain of the virus, our clinical experience in children is limited because we have had only a few cases so far. “Rash or skin lesions are typical, and fever and swollen lymph nodes (lymphadenopathy) are also common symptoms. However, children may be at higher risk of more severe disease and complications from monkeypox, particularly if they are very young, have skin conditions like eczema, or are immunocompromised.” If you are a journalist looking to cover this topic, let us help with your stories. Paulo Verardi is a virologist who specializes in vaccine research and development and is a member of the Center of Excellence for Vaccine Research. Dr. Verardi is available to speak with media regarding virology, monkeypox, COVID-19, and other viruses – simply click on his icon now to arrange an interview today.

Paulo Verardi, Associate Professor of Virology and Vaccinology at UConn, was asked to lend his expertise and opinion to The Conversation about coronavirus variants and just how concerned Americans should be about the emergence of variants and the speed at which they are spreading across the country and the globe. Spring has sprung, and there is a sense of relief in the air. After one year of lockdowns and social distancing, more than 171 million COVID-19 vaccine doses have been administered in the U.S. and about 19.4% of the population is fully vaccinated. But there is something else in the air: ominous SARS-CoV-2 variants. I am a virologist and vaccinologist, which means that I spend my days studying viruses and designing and testing vaccine strategies against viral diseases. In the case of SARS-CoV-2, this work has taken on greater urgency. We humans are in a race to become immune against this cagey virus, whose ability to mutate and adapt seems to be a step ahead of our capacity to gain herd immunity. Because of the variants that are emerging, it could be a race to the wire. April 08 The Conversation  Dr. Verardi discusses the the five SARS-CoV-2 variants we all need to be watching, the rates of transmission and the severity of symptoms, and why we all need to remain on guard and get vaccinated. It is a great article, and if you are a journalist looking to cover this topic, then let us help with your stories. Dr. Paulo Verardi is a virologist who specializes in vaccine research and development and is a member of the Center of Excellence for Vaccine Research. Dr. Verardi is available to speak with media regarding variants and COVID-19 – simply click on his icon now to arrange an interview today.